These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 28743299)
1. The public health value of vaccines beyond efficacy: methods, measures and outcomes. Wilder-Smith A; Longini I; Zuber PL; Bärnighausen T; Edmunds WJ; Dean N; Spicher VM; Benissa MR; Gessner BD BMC Med; 2017 Jul; 15(1):138. PubMed ID: 28743299 [TBL] [Abstract][Full Text] [Related]
2. Beyond efficacy: The full public health impact of vaccines. Saadatian-Elahi M; Horstick O; Breiman RF; Gessner BD; Gubler DJ; Louis J; Parashar UD; Tapia R; Picot V; Zinsou JA; Nelson CB Vaccine; 2016 Feb; 34(9):1139-47. PubMed ID: 26808648 [TBL] [Abstract][Full Text] [Related]
3. [From the licensure of vaccines to the recommendation of the Standing Committee on Vaccination in Germany : criteria for the assessment of benefits and risks]. Pfleiderer M; Wichmann O Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):263-73. PubMed ID: 25566841 [TBL] [Abstract][Full Text] [Related]
4. Estimating the full public health value of vaccination. Gessner BD; Kaslow D; Louis J; Neuzil K; O'Brien KL; Picot V; Pang T; Parashar UD; Saadatian-Elahi M; Nelson CB Vaccine; 2017 Nov; 35(46):6255-6263. PubMed ID: 28986035 [TBL] [Abstract][Full Text] [Related]
5. Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate. Gessner BD; Wilder-Smith A Vaccine; 2016 Apr; 34(20):2397-401. PubMed ID: 27055020 [TBL] [Abstract][Full Text] [Related]
6. The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials. Black S Expert Rev Vaccines; 2015; 14(12):1543-8. PubMed ID: 26414015 [TBL] [Abstract][Full Text] [Related]
7. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
8. Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness. Wichmann O; Vannice K; Asturias EJ; de Albuquerque Luna EJ; Longini I; Lopez AL; Smith PG; Tissera H; Yoon IK; Hombach J Vaccine; 2017 Oct; 35(42):5535-5542. PubMed ID: 28893477 [TBL] [Abstract][Full Text] [Related]
9. Vaccine effects and impact of vaccination programmes in post-licensure studies. Hanquet G; Valenciano M; Simondon F; Moren A Vaccine; 2013 Nov; 31(48):5634-42. PubMed ID: 23856332 [TBL] [Abstract][Full Text] [Related]
10. Using the impact of pneumococcal vaccines on nasopharyngeal carriage to aid licensing and vaccine implementation; a PneumoCarr meeting report March 27-28, 2012, Geneva. Goldblatt D; Ramakrishnan M; O'Brien K Vaccine; 2013 Dec; 32(1):146-52. PubMed ID: 23933374 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516 [TBL] [Abstract][Full Text] [Related]
12. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy]. Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779 [TBL] [Abstract][Full Text] [Related]
13. Vaccination of children with a live-attenuated, intranasal influenza vaccine - analysis and evaluation through a Health Technology Assessment. Andersohn F; Bornemann R; Damm O; Frank M; Mittendorf T; Theidel U GMS Health Technol Assess; 2014; 10():Doc03. PubMed ID: 25371764 [TBL] [Abstract][Full Text] [Related]
14. [The new National Immunization Program 2017-2019 and the Essential Care Levels: what is going to change?]. De Waure C; Sisti LG; Poscia A; Ricciardi W Ig Sanita Pubbl; 2017; 73(5):405-418. PubMed ID: 29433128 [TBL] [Abstract][Full Text] [Related]
15. Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy. Gessner BD; Feikin DR Vaccine; 2014 May; 32(26):3133-8. PubMed ID: 24731817 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial. Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293 [TBL] [Abstract][Full Text] [Related]
17. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). Wharton M; Strikas RA; Harpaz R; Rotz LD; Schwartz B; Casey CG; Pearson ML; Anderson LJ; ; MMWR Recomm Rep; 2003 Apr; 52(RR-7):1-16. PubMed ID: 12710832 [TBL] [Abstract][Full Text] [Related]
18. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age. Allsup S; Gosney M; Haycox A; Regan M Health Technol Assess; 2003; 7(24):iii-x, 1-65. PubMed ID: 14499051 [TBL] [Abstract][Full Text] [Related]
19. Challenges in evaluating post-licensure vaccine safety: observations from the Centers for Disease Control and Prevention. Moro PL; Haber P; McNeil MM Expert Rev Vaccines; 2019 Oct; 18(10):1091-1101. PubMed ID: 31580725 [No Abstract] [Full Text] [Related]